The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | FORTE: MRD by MFC or NGS in myeloma
Francesca Gay, MD, PhD, University of Turin, Turin, Italy, discusses the results of a study comparing the impact of measurable residual disease (MRD), by multiparameter flow cytometry (MFC) and next-generation sequencing (NGS), on outcomes in patients with newly diagnosed transplant-eligible multiple myeloma. Patients from the FORTE trial (NCT02203643) and the rate of conversion from MRD-positive to MRD-negative was assessed in different treatment arms. The treatment arms included carfilzomib-lenalidomide-dexamethasone (KRd) followed by autologous stem cell transplant (ASCT) and KRd consolidation, KRd alone for 12 cycles, or lenalidomide-cyclophosphamide-dexamethasone (KCd) induction followed by ASCT and KCd consolidation. High rates of positive to negative MRD conversion and sustained MRD-negativity were observed with KRd-transplant by both MFC and NGS, compared to the other two arms. Additionally, a high degree of concordance was observed between MFC and NGS techniques. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
